Aspira Women's Health Inc. (AWHL) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Aspira Women's Health Inc. (AWHL) stock forecast summary
Our AI ranks Aspira Women's Health Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Aspira Women's Health Inc. is a small-cap company with a market capitalization of $12M. It ranks number 12 by market capitalization among the 15 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for AWHL is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, AWHL included.
Follow AWHL freeAWHL price chart and AI forecast
How AWHL ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Aspira Women's Health Inc. (AWHL) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | AWHL | Rank |
|---|---|---|
| Market Cap | $12M | 12/15 |
| EPS | $-0.14 | – |
Profitability & Margins
| Metric | AWHL | Rank |
|---|---|---|
| Operating Margin | -3271.8% | 12/14 |
| EBT Margin | -2003.5% | 11/14 |
Financial Health
| Metric | AWHL | Rank |
|---|---|---|
| Current Ratio | 0.52x | 14/15 |
| Quick Ratio | 0.48x | 9/9 |
| Interest Coverage | 8.1x | 5/14 |
| Working Capital | -$3M | 13/15 |
Cash Flow
| Metric | AWHL | Rank |
|---|---|---|
| Operating Cash Flow | -$5M | 7/16 |
Operational Efficiency
| Metric | AWHL | Rank |
|---|---|---|
| Inventory Turnover | 15.6x | 1/9 |
| Days Inventory | 23 days | 9/9 |
| Payables Period | 279 days | 2/9 |
Income Statement
| Metric | AWHL | Rank |
|---|---|---|
| Operating Income | -$7M | 6/15 |
| R&D Expense | $3M | 11/16 |
| SG&A Expense | $10M | 10/12 |
| Cost of Goods Sold | $4M | 9/10 |
Dividend & Shareholder Information
| Metric | AWHL | Rank |
|---|---|---|
| Shares Outstanding | 47M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $3M | |
| Cash & Short-term Investments | $480K | |
| Accounts Receivable | $1M | |
| Inventory | $230K | |
| Total Liabilities | $12M | |
| Short-term Debt | $3M |
AWHL quarterly financials and insider trading
Aspira Women's Health Inc. (AWHL) industry peers
Companies classified under the same SEC industry code as Aspira Women's Health Inc. (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| AWHL Aspira Women's Health Inc. | ▲ | $12M |
| IDXX Idexx Laboratories Inc /De | ▼ | $40.99B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.53B |
| NEOG Neogen Corp | ▲ | $2.56B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.22B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.67B |
| QDEL Quidelortho Corp | ▶ | $967M |
| ACHV Achieve Life Sciences, Inc. | ▶ | $720M |
| TKNO Alpha Teknova, Inc. | ▲ | $441M |
| MYGN Myriad Genetics Inc | ▲ | $390M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| ICCC Immucell Corp /De/ | ▲ | $87M |
| BMRA Biomerica Inc | ▲ | $8M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▶ | $5M |
| VNRX Volitionrx Ltd | ▼ | $3M |
| QCLS Q/C Technologies, Inc. | ▼ | N/A |
| TRIB Trinity Biotech Plc | ▼ | N/A |
Where AWHL sits on the market map
Aspira Women's Health Inc. (AWHL) stock news
Loading...
Aspira Women's Health Inc. (AWHL) stock forecast FAQ
What is the Aspira Women's Health Inc. (AWHL) stock forecast?
Our AI ranks Aspira Women's Health Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Aspira Women's Health Inc. stock predictions?
A per-ticker accuracy statistic for AWHL is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Aspira Women's Health Inc. forecasts updated?
Aspira Women's Health Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Aspira Women's Health Inc.'s industry peers?
17 issuers in our coverage, AWHL included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.